Clinical Trials for Mesothelioma Patients—Vaccine Therapy and GM-CSF

Read about the concurrent therapy for a current clinical trial to test vaccine therapy GM-CSF on mesothelioma patients. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Rationale:

Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from growing. Giving vaccine therapy together with GM-CSF may kill more cancer cells.

Purpose:

This phase I trial is studying the side effects of vaccine therapy and GM-CSF in treating patients with acute myeloid leukemia, myelodysplastic syndromes, non-small cell lung cancer, or mesothelioma.

Phase, Condition and Intervention:

Phase I; Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes Peritoneal Cavity Cancer; Drug: WT-1 analog peptide vaccine, Drug: incomplete Freund's adjuvant, Drug: sargramostim, Procedure: flow cytometry, Procedure: immunoenzyme technique, Procedure: polymerase chain reaction

Study Type and Design:

Interventional treatment

Official Title: Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Thoracic and Myeloid Neoplasms

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.